MedCentral: Pros and cons of intermittent fasting on cardiovascular health
The University of Cincinnati's Richard Becker commented to MedCentral on a recent study that found people who limit their eating to an 8-hour period each day had a 91% greater risk of cardiovascular death than those who ate during a window of 12 to 16 hours.
This method of restricted eating is often called intermittent fasting or time-restricted eating (TRE). Researchers also found that study participants living with heart disease faced a 66% higher risk of death from heart disease or stroke, while TRE did not appear to reduce the risk of death from any cause.
Becker suggested caution in coming to any concrete conclusions on the risks and benefits of TRE at this point.
"There may be favorable metabolic trends, such as improving insulin resistance and glycemic control,” associated with intermittent fasting, said Becker, professor, director and physician-in-chief at the UC Heart, Lung and Vascular Institute and UC Division of Cardiovascular Health and Disease at the UC College of Medicine. But, he added, “we do not have sufficiently strong or convincing evidence that time-restricted eating is either efficacious or safe. Further research will be required before recommendations to the public can be made.”
Featured photo at top of table place setting. Photo/Christopher Jolly/Unsplash.
Related Stories
UC biologist talks about 'pearmageddon'
March 16, 2026
WLWT talks to UC biologist and Department Head Theresa Culley about invasive, nonnative Callery pear trees that are spreading across Ohio forests after they were introduced by landscapers more than 50 years ago.
Local media highlight completion of Blood Cancer Healing Center fourth and fifth floors
March 16, 2026
Local media including WLWT and the Cincinnati Business Courier highlighted the opening of research laboratories and the UC Osher Wellness Suite and Learning Kitchen at the University of Cincinnati Cancer Center’s Blood Cancer Healing Center.
Trial results support weekly buprenorphine treatment of opioid use disorder during pregnancy
March 16, 2026
Supported by the National Institutes of Health (NIH), researchers led by the University of Cincinnati's John Winhusen published clinical trial results in JAMA Internal Medicine that found administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder during pregnancy led to higher rates of abstinence from illicit opioids than buprenorphine given daily under the tongue, one of the standard methods of treatment.